Novagali launches dry eye treatment Cationorm

Article

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

The emulsion, which uses Novasorb technology, acts on the different levels of the tear film. Novasorb, a proprietary platform of Novagali's, uses the electrostatic attraction between the positively charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.

Cationorm combines lubricating and hydrating properties to replenish the tear film lipid layer and prevent tear evaporation. Clinical studies have proven the efficacy of Cationorm in treating dry eye symptoms, and it is associated with increased tolerance and comfort.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.